A recent study suggests a potential link between Ozempic and vision loss, particularly non-arteritic anterior ischemic optic ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted ...

One observation I would make about the GLP-1 / incretin mimetic class of drugs is that they are clearly difficult to develop. Lilly and Novo have been working with this drug class for >30 years ...

GLP-1-based therapy: incretin mimetics (GLP-1 analogues) and incretin enhancers (DPP-4 inhibitors) are now available for the treatment of Type 2 diabetes. Initial combination therapy with a DPP-4 ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and ...

More recently, pharmacological Caloric Restriction Mimetics (CRMs) have gained interest of the public and scientific community as promising candidates that mimic some of the myriad of effects induced ...

Molecular Cancer Therapeutics publishes articles on the discovery and preclinical development of novel therapeutic agents for oncology, preclinical studies of approved therapeutics, mechanisms of drug ...